StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) company profile

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.70−0.06 (-1.26%)

Close on Nov 17, 2026Market cap $290.66MP/E –Yield –

About Kyverna Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Kyverna Therapeutics, Inc. is a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The company concentrates primarily on its neuroimmunology CAR T franchise to achieve immune reset and treatment-free remission. Its lead product candidate is mivocabtagene autoleucel (miv-cel, or KYV-101), an autologous, fully human CD19-targeting CAR T-cell therapy being developed for serious conditions including stiff person syndrome and generalized myasthenia gravis. Additionally, the company explores pipeline expansion into other autoimmune indications such as progressive multiple sclerosis, rheumatoid arthritis, lupus nephritis, and systemic sclerosis, as well as novel manufacturing platforms such as KYV-102.

The company's clinical research is supported by data from investigator-initiated trials at leading academic institutions and company-sponsored clinical trials across various autoimmune indications. Kyverna maintains its principal executive offices in Emeryville, California.

Summary of the business section of Kyverna Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Kyverna Therapeutics, Inc.
Headquarters
Emeryville, CA
Address
5980 Horton Street, Suite 200
Phone
(510) 925-2492
Employees
130, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BDO USA, P.C., San Diego, California

Stock & identifiers

Ticker
KYTX
Exchange
Nasdaq
IPO date
Feb 8, 2024
Shares outstanding
62M, Aug 3, 2026
Public float
$64.50M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1994702
CUSIP
501976104
ISIN
US5019761049
FIGI
BBG00RCYMHR1
Share class FIGI
BBG00RCYMHS0
EIN
83-1365441

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Christi ShawExecutive Chairperson, Director66,741
Warner Weston BiddleChief Executive Officer, Director58,000
Gregory S. MartiniChief Financial Officer–
Nadia DacChief Commercial Officer–
Marc GrassoChief Financial Officer10,000
Naji GehchanSee Remarks18,000
Mayobanex PujolsChief Technology Officer–
Karen Marie WalkerChief Technology Officer22,636
Ryan Alexander JonesChief Financial Officer55,950
Fred E. CohenDirector4,545,651
Beth C. SeidenbergDirector891,044
Ian T. ClarkDirector21,727
Mert AktarDirector21,727
Andrew Craig MillerDirector11,006
Sravan Kumar EmanyDirector11,006
Daniel K. SpiegelmanDirector16,634

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Warner Biddle
Chief Executive Officer
$625.00K–$543.80K$468.75K$177.43K$1.81M-88%
Marc Grasso, M.D.
Chief Financial Officer
$256.96K$100.00K$1.10M$204.00K$2.55K$1.66M–
Naji Gehchan, M.D.
Chief Medical and Development Officer
$481.67K$250.00K$1.11M$238.41K$5.00K$2.09M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 8, 2024
Offer price
$22.00
Securities offered
14,500,000
Gross proceeds
$319.00M
Exchange
Nasdaq
First trading day
Feb 8, 2024
First-day close
$30.00+36.4%
Lock-up ends (est.)
Aug 6, 2024

“The initial public offering price per share is $22.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 1, 2026, we had 130 employees, all of whom were full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?